Abstract
Over the past decade, substantial progress has been made from NGS primary tumor single biopsy to multiple tumoral and liquid biopsies. The evidence of extensive genetic and transcriptomic heterogeneity suggest the urgent need for the development of multiple agents as druggable biomarkers for the selection of most effective combination of drugs for every individual patient. Emerging validation trials on genomic and trasncriptomic analysis could provide potential clinical implications.

(Citation: Gastric & Breast Cancer 2019; 14(1) 22-27)

Back

PDF Version